Jounce Therapeutics Inc

NASDAQ:JNCE  
7.05
-0.32 (-4.34%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)346.33M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.07 Million
Adjusted EPS-$0.48
See more estimates
10-Day MA$7.55
50-Day MA$8.58
200-Day MA$8.95
See more pivots

Jounce Therapeutics Inc Stock, NASDAQ:JNCE

780 Memorial Drive, Cambridge, Massachusetts 02139
Phone: +1.857.259.3840
Number of Employees: 128

Description

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.